Advertisement

Long-Term Trends in Allograft Survival

  • Daniel C. Brennan
    Correspondence
    Address correspondence to Daniel C. Brennan, MD, Washington University School of Medicine, 6107 Queeny Tower, One Barnes-Jewish Hospital Plaza, St. Louis, MO 63110.
    Affiliations
    Washington University School of Medicine, St. Louis, MO.
    Search for articles by this author
      Kidney transplantation has changed dramatically over the past decade. Many advances have occurred that result in shorter hospital stays, decreased acute rejection, less infectious morbidity, and improved long-term allograft survival. Many factors are responsible for the improvement in kidney transplantation, and these factors are discussed in this review. These successes have led to a paradox in the care of the kidney-transplant recipient, however. As the short-term complications are prevented or successfully managed, more patients will develop chronic problems with the function of the allograft.

      Index Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Advances in Chronic Kidney Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Merrill J.P.
        • Murray J.E.
        • Harrison J.H.
        • et al.
        Successful homotransplantation of the human kidney between identical twins.
        JAMA. 1956; 160: 277-282
        • Norman D.J.
        • Shield 3rd, C.F.
        • Barry J.
        • et al.
        Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection.
        Am J Kidney Dis. 1988; 2: 107-110
        • Shapiro R.
        • Young J.B.
        • Milford E.L.
        • et al.
        Immunosuppression.
        Am J Transplant. 2005; 5: 874-886
        • Danovitch G.M.
        • Cohen D.J.
        • Weir M.R.
        • et al.
        Current status of kidney and pancreas transplantation in the United States, 1994-2003.
        Am J Transplant. 2005; 5: 904-915
        • Preiksaitis J.K.
        • Brennan D.C.
        • Fishman J.
        • et al.
        Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation.
        Am J Transplant. 2005; 5: 218-227
        • Solez K.
        • Axelsen R.A.
        • Benediktsson H.
        • et al.
        International standardization of criteria for the histologic diagnosis of renal allograft rejection.
        Kidney Int. 1993; 2: 411-422
        • Racusen L.C.
        • Halloran P.F.
        • Solez K.
        Banff 2003 meeting report.
        Am J Transplant. 2004; 4: 1562-1566
        • Hariharan S.
        • Johnson C.P.
        • Bresnahan B.A.
        • et al.
        Improved graft survival after renal transplantation in the United States, 1988 to 1996.
        N Engl J Med. 2000; 342: 605-612
        • Meier-Kriesche H.U.
        • Schold J.D.
        • Kaplan B.
        Long-term renal allograft survival.
        Am J Transplant. 2004; 8: 1289-1295
        • Meier-Kriesche H.U.
        • Schold J.D.
        • Srinivas T.R.
        • et al.
        Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.
        Am J Transplant. 2004; 8: 378-383
        • Keith D.S.
        • DeMattos A.
        • Golconda M.
        • et al.
        Factors associated with improvement in deceased donor renal allograft function in the 1990s.
        J Am Soc Nephrol. 2005; 5: 1512-1521
      1. U.S. Renal Data System: USRDS 2003 annual data report: Atlas of end-stage renal disease in the United States. National Institutes of Health, National Institutes of Diabetes & Digestive Kidney Diseases, Bethesda, MD2003
        • Pascual M.
        • Theruvath T.
        • Kawai T.
        • et al.
        Strategies to improve long-term outcomes after renal transplantation.
        N Engl J Med. 2002; 346: 580-590
      2. Prasad SA, Kasiske BLMD, Curtis JJ, et al: Impact and management of cardiovascular risks after kidney transplantation. Accessed July 31, 2005 at www.medscape.com/viewprogram/4237_pnt.

        • Wolfe R.A.
        • Ashby V.B.
        • Milford E.L.
        • et al.
        Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.
        N Engl J Med. 1999; 341: 1725-1730
        • Meier-Kriesche H.U.
        • Baliga R.
        • Kaplan B.
        Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation.
        Transplantation. 2003; 75: 1291-1295
        • Meier-Kriesche H.U.
        • Schold J.D.
        • Srinivas T.R.
        • et al.
        Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease.
        Am J Transplant. 2004; 10: 1662-1668
        • Woodward R.S.
        • Kutinova A.
        • Ricci J.-F.
        • et al.
        The incidence and accumulative costs of sepsis and pneumonia before and after renal transplantation in the United States. XX International Congress of the Transplantation Society, Vienna, Austria, Abstract P840.
        Transplantation. 2004; 782: 495
        • Sagedal S.
        • Hartmann A.
        • Nordal K.P.
        • et al.
        Impact of early cytomegalovirus infection and disease in long-term recipient and kidney graft survival.
        Kidney Int. 2004; 66: 329-337
        • Wang C.D.T.
        Cancer after kidney transplantation in the United States.
        Am J Transplant. 2004; 6: 905-913
        • Guba M.
        • Graeb C.
        • Jauch K.W.
        • et al.
        Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation.
        Transplantation. 2004; 12: 1777-1782
        • Stallone G.
        • Schena A.
        • Infante B.
        • et al.
        Sirolimus for Kaposi’s sarcoma in renal-transplant recipients.
        N Engl J Med. 2005; 352: 1317-1323
        • Nankivell B.J.
        • Borrows R.J.
        • Fung C.L.
        • et al.
        Calcineurin inhibitor nephrotoxicity.
        Transplantation. 2004; 78: 557-565
        • Burke Jr, J.F.
        • Pirsch J.D.
        • Ramos E.L.
        • et al.
        Long-term efficacy and safety of cyclosporine in renal-transplant recipients.
        N Engl J Med. 1994; 331: 358-363
        • Woodward R.S.
        • Schnitzler M.A.
        • Baty J.
        • et al.
        Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients.
        Am J Transplant. 2003; 3: 590-598
        • Woodward R.S.
        • Kutinova A.
        • Schnitzler M.A.
        • et al.
        Renal graft survival and calcineurin inhibitor.
        Transplantation. 2005; 80: 629-633
        • Hirsch H.H.
        • Brennan D.C.
        • Drachenberg C.B.
        • et al.
        Polyomavirus-associated nephropathy in renal transplantation.
        Transplantation. 2005; 79: 1277-1286
        • Brennan D.C.
        • Agha I.
        • Bohl D.L.
        • et al.
        Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction.
        Am J Transplant. 2005; 5: 582-594
        • Flechner S.M.
        • Kurian S.M.
        • Solez K.
        • et al.
        De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years.
        Am J Transplant. 2004; 4: 1776-1785
        • Kreis H.
        • Oberbauer R.
        • Campistol J.M.
        • et al.
        Rapamune Maintenance Regimen Trial.
        J Am Soc Nephrol. 2004; 15: 809-817
        • Marti H.P.
        • Frey F.J.
        Nephrotoxicity of rapamycin.
        Nephrol Dial Transplant. 2005; 20: 13-15
        • Gallagher M.P.
        • Hall B.
        • Craig J.
        • et al.
        Australian Multicenter Trial of Cyclosporine Withdrawal Study Group and the ANZ Dialysis and Transplantation Registry: A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results.
        Transplantation. 2004; 78: 1653-1660
      3. Miller BW, Brennan DC: Withdrawal or avoidance of corticosteroids after renal transplantation. UpToDate online v13.2 20005 @www.uptodate.com

        • Halloran P.F.
        Call for revolution.
        Am J Transplant. 2002; 2: 195-200